Journal
NATURE REVIEWS NEUROLOGY
Volume 14, Issue 8, Pages 454-456Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41582-018-0033-8
Keywords
-
Categories
Ask authors/readers for more resources
Eteplirsen, a compound designed to restore dystrophin in patients with Duchenne muscular dystrophy, controversially received approval by the FDA in 2016. Owing to limited clinical data, the approval was based on eteplirsen's effect on dystrophin expression. Now, the dystrophin quantification results have been published, and although low levels of dystrophin expression are shown, the quantification remains debatable.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available